Livforsakringsbolaget Skandia Omsesidigt Has $5.89 Million Stake in Quest Diagnostics Inc (DGX)
Livforsakringsbolaget Skandia Omsesidigt cut its position in Quest Diagnostics Inc (NYSE:DGX) by 6.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 59,835 shares of the medical research company’s stock after selling 4,300 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Quest Diagnostics were worth $5,893,000 at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of the company. Thrivent Financial For Lutherans raised its position in shares of Quest Diagnostics by 2.0% in the 2nd quarter. Thrivent Financial For Lutherans now owns 5,200 shares of the medical research company’s stock valued at $578,000 after buying an additional 100 shares in the last quarter. D.A. Davidson & CO. raised its position in shares of Quest Diagnostics by 1.2% in the 2nd quarter. D.A. Davidson & CO. now owns 12,788 shares of the medical research company’s stock valued at $1,421,000 after buying an additional 147 shares in the last quarter. Signet Financial Management LLC raised its position in shares of Quest Diagnostics by 0.3% in the 2nd quarter. Signet Financial Management LLC now owns 72,531 shares of the medical research company’s stock valued at $8,063,000 after buying an additional 210 shares in the last quarter. WFG Advisors LP raised its position in shares of Quest Diagnostics by 45.3% in the 2nd quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock valued at $107,000 after buying an additional 301 shares in the last quarter. Finally, Veritable L.P. raised its position in shares of Quest Diagnostics by 5.3% in the 2nd quarter. Veritable L.P. now owns 6,515 shares of the medical research company’s stock valued at $724,000 after buying an additional 326 shares in the last quarter. Institutional investors own 88.92% of the company’s stock.
Quest Diagnostics Inc (DGX) opened at $101.49 on Thursday. The company has a current ratio of 1.47, a quick ratio of 1.37 and a debt-to-equity ratio of 0.78. Quest Diagnostics Inc has a 12-month low of $90.10 and a 12-month high of $112.96. The stock has a market cap of $13,796.22, a P/E ratio of 21.28, a P/E/G ratio of 2.00 and a beta of 0.60.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 9th will be given a $0.45 dividend. This represents a $1.80 annualized dividend and a yield of 1.77%. The ex-dividend date is Monday, January 8th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 37.74%.
In other Quest Diagnostics news, EVP J. E. Davis sold 63,880 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $98.68, for a total value of $6,303,678.40. Following the completion of the transaction, the executive vice president now directly owns 101,423 shares in the company, valued at approximately $10,008,421.64. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.75% of the company’s stock.
DGX has been the subject of several analyst reports. Canaccord Genuity restated a “buy” rating and issued a $110.00 target price on shares of Quest Diagnostics in a research report on Tuesday. Wells Fargo & Co started coverage on shares of Quest Diagnostics in a research report on Thursday, October 12th. They issued a “market perform” rating and a $88.00 target price for the company. Raymond James Financial reiterated a “market perform” rating on shares of Quest Diagnostics in a research report on Monday, September 25th. Goldman Sachs Group cut shares of Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and lowered their price objective for the stock from $121.00 to $113.00 in a research report on Tuesday, October 10th. Finally, KeyCorp reiterated a “hold” rating on shares of Quest Diagnostics in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $106.45.
Quest Diagnostics Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.